Table 1

Demographic and baseline characteristics of patients with AOSD treated with tadekinig alfa

All
(n=23)
80 mg (group 1)
(n=10)
160 mg (group 2)
(n=13)
Age, years41 (30–58.5)49.5 (34.2–58.7)35 (30–58)
Gender (male/female)7/164/63/10
BMI, kg/m2 25.33 (23–27.5)24.5 (23.1–34.5)25.4 (22.4–26.4)
Disease duration, months15 (6.5–42.2)25.5 (8.7–44.2)11.6 (2.1–37.6)
No of previous flares, n (%)
 07 (30.4)2 (20)5 (38.46)
 12 (8.69)1 (10)1 (7.69)
 25 (21.73)2 (20)3 (23.07)
 ≥33 (13.04)3 (30)0
 Unknown6 (26.08)2 (20)4 (30.76)
Baseline disease manifestations, n (%)
 Skin rash13 (56.52)7 (70)6 (46.15)
 Arthritis/arthralgia19 (82.6)8 (80)11 (84.6)
 Swollen joints16 (69.5)6 (60)10 (76.92)
 Tender joints18 (78.26)8 (80)10 (76.92)
 SJC*4 (0–5)2.5 (0–4.75)4 (3–5)
 TJC*6 (1–11.5)7 (4–12)6 (1–8)
 Fever2 (8.70)02 (15.38)
 Neutrophilia (>8  g/L)14 (60.86)5 (50)9 (69.23)
Comorbidities21 (91.3)10 (100)11 (84.61)
Previous treatments, n (%)
 NSAIDs14 (65.21)7 (70)7 (53.84)
 Glucocorticoids22 (96)10 (100)12 (92)
  Prednisone dose (mg/day)30 (7.9–50)35 (30–50)15 (7.5–32.5)
  csDMARDs13 (56.5)6 (60)7 (53.8)
  1 csDMARD9 (39.1)5 (50)4 (30.8)
  ≥2 csDMARDs4 (17.4)1 (10)3 (23)
Previous csDMARD therapy, n (%)
 MTX11 (47.82)5 (50)6 (46.15)
 LFN1 (4.3)01 (7.69)
 MMF1 (4.3)1 (10)0
 Antimalarials3 (13)1 (10)2 (15.4)
Patients with bDMARDs, n (%)9 (39.1)4 (40)5 (38.5)
 1 bDMARD4 (17.4)1 (10)3 (23)
 ≥2 bDMARDs5 (21.7)3 (30)2 (15.4)
Previous bDMARD therapy, n (%)
 Anakinra6 (26.08)4 (40)2 (15.38)
 Canakinumab3 (13.04)2 (20)1 (7.69)
 Etanercept2 (8.7)1 (10)1 (7.69)
 Tocilizumab3 (13.04)03 (23.07)
 Rituximab1 (4.3)01 (7.69)
 Abatacept1 (4.3)01 (7.69)
Concomitant treatments, n (%)
 NSAIDs12 (52.2)8 (80)7 (53.84)
 Glucocorticoids21 (91.30)10 (100)11 (84.61)
 MTX7 (26.08)5 (50)2 (15.38)
 LFN1 (4.3)01 (7.69)
 MMF1 (4.3)1 (10)0
  • Data are n/N (%) or median (IQR), unless stated otherwise.

  • *According to a 44-joint assessment.

  • AOSD, adult-onset Still’s disease; bDMARDs, biological disease-modifying antirheumatic drugs; BMI, body mass index; csDMARDs, conventional synthetic disease-modifying antirheumatic drugs; LFN, leflunomide; MMF, mycophenolate mofetil; MTX, methotrexate; NSAIDs, non-steroidal anti-inflammatory drugs; SJC, swollen joint count; TJC, tender joint count.